JMP Securities analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and raises the price target from $42 to $45.
JMP Securities Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $45
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.